reverse phase protein array

This Week in PLOS

In PLOS this week: genomic analysis of honeybee disease, microRNA profiles of people with lupus nephritis, and more.

An integrated analysis of uterine carcinosarcomas uncovered a range of somatic mutations and shifts in transcription, methylation, and microRNA expression.

The marker has the potential to improve upon existing markers like HER2 and HR status while also expanding the population of patients considered for neratinib treatment.

Led by Gordon Mills, chair of systems biology at the University of Texas MD Anderson Cancer Center, a group of researchers is developing a database containing proteomic characterizations of thousands of cancer patient samples and cell lines.

A team led by researchers at George Mason University has completed a phosphoproteomic analysis of the National Cancer Institute-60, a set of 60 human cancer cell lines.

Theranostics Health this week announced the June launch of its first commercial test, a 14-protein assay for profiling activation of the HER signaling network.

A recent investigation by the National Cancer Institute's Cancer Genome Atlas consortium into the genetic underpinnings of breast tumors also offers a glimpse of the benefits of including proteomic data in such analyses.

Researchers from the MD Anderson Cancer Center have identified PARP1 and several other proteins as potential drug targets in small cell lung cancer using reverse-phase protein arrays to compare proteins in small cell and non-small cell lung cancer cell lines.

With a recent market development agreement with clinical trial services company Med Fusion, Theranostics Health continues its push to bring its first protein diagnostic product to market in early 2013.

Molecular diagnostics firm Theranostics Health plans to commercially launch the first of its TheraLink diagnostic assays by the first quarter of next year, company officials told ProteoMonitor this week.

Pages

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.